Zanubrutinib Levels and Effects while Breastfeeding
Summary of Use during Lactation
No information is available on the clinical use of zanubrutinib during breastfeeding. Because zanubrutinib is 94% bound to plasma proteins, the amount in milk is likely to be low. The manufacturer recommends that breastfeeding be discontinued during zanubrutinib therapy and for at least 2 weeks after the last dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Zanubrutinib
CAS Registry Number
1691249-45-2
Drug Class
Breast Feeding
Lactation
Antineoplastic Agents
Enzyme Inhibitors
Hematologic Agents
Protein Kinase Inhibitors
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
